دورية أكاديمية
Isoliquiritigenin limits inflammasome activation of macrophage via docking into Syk to alleviate murine non-alcoholic fatty liver disease.
| العنوان: | Isoliquiritigenin limits inflammasome activation of macrophage via docking into Syk to alleviate murine non-alcoholic fatty liver disease. |
|---|---|
| المؤلفون: | Hu X; Department of Gastroenterology, Yangzhou Key Laboratory for Precision Treatment of Refractory Bowel Diseases, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.; Department of Basic Medicine, School of Medicine, Yangzhou University, Yangzhou, China., Hu C; Department of Basic Medicine, School of Medicine, Yangzhou University, Yangzhou, China., Liao L; Department of Basic Medicine, School of Medicine, Yangzhou University, Yangzhou, China., Zhang H; Department of Basic Medicine, School of Medicine, Yangzhou University, Yangzhou, China., Xu X; Department of Gastroenterology, Yangzhou Key Laboratory for Precision Treatment of Refractory Bowel Diseases, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China., Xiang J; Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, China., Lu G; Department of Gastroenterology, Yangzhou Key Laboratory for Precision Treatment of Refractory Bowel Diseases, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.; Department of Gastroenterology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China., Jia X; Department of Basic Medicine, School of Medicine, Yangzhou University, Yangzhou, China., Xu H; Kunshan Hospital of Traditional Chinese Medicine, Kunshan Affiliated Hospital of Yangzhou University, Kunshan, China., Gong W; Department of Gastroenterology, Yangzhou Key Laboratory for Precision Treatment of Refractory Bowel Diseases, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.; Department of Basic Medicine, School of Medicine, Yangzhou University, Yangzhou, China.; Department of Gastroenterology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.; Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou, China.; Jiangsu Key Laboratory of Zoonosis, Yangzhou, China. |
| المصدر: | Scandinavian journal of immunology [Scand J Immunol] 2024 Jul; Vol. 100 (1), pp. e13371. Date of Electronic Publication: 2024 Apr 26. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 0323767 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-3083 (Electronic) Linking ISSN: 03009475 NLM ISO Abbreviation: Scand J Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Blackwell Scientific Publications Original Publication: Oslo, Universitetsforlaget. |
| مواضيع طبية MeSH: | Syk Kinase*/metabolism , Chalcones*/pharmacology , Inflammasomes*/metabolism , Inflammasomes*/drug effects , Macrophages*/immunology , Macrophages*/metabolism , Macrophages*/drug effects , Non-alcoholic Fatty Liver Disease*/drug therapy , Non-alcoholic Fatty Liver Disease*/metabolism , Non-alcoholic Fatty Liver Disease*/immunology , Mice, Transgenic*, Animals ; Mice ; Macrophage Activation/drug effects ; Mice, Inbred C57BL ; Molecular Docking Simulation ; Male ; Phosphorylation ; Disease Models, Animal |
| مستخلص: | Isoliquiritigenin (ISL) is a chalcone-type flavonoid derived from the root of licorice with antioxidant, anti-inflammatory, anti-tumour and neuroprotective properties. ISL has been proven to downregulate the productions of IL-1β, TNF-α and IL-6 by macrophages. However, detailed molecular mechanisms of this modulation remain elusive. Here, ISL suppressed Syk phosphorylation and CD80, CD86, IL-1β, TNF-α and IL-6 expressions in lipopolysaccharide-stimulated macrophages ex vivo. ApoC3-transgenic (ApoC3 TG ) mice had more activated macrophages. ISL was also able to downregulate the inflammatory activities of macrophages from ApoC3 TG mice. Administration of ISL inhibited Syk activation and inflammatory activities of macrophages in ApoC3 TG mice in vivo. The treatment of ISL further alleviated MCD-induced non-alcoholic fatty liver disease (NAFLD) in wild-type and ApoC3 TG mice, accompanied by less recruitment and activation of liver macrophages. Due to the inhibition of Syk phosphorylation, ISL-treated macrophages displayed less production of cytoplasmic ROS, NLRP3, cleaved-GSDMD and cleaved-IL-1β, suggesting less inflammasome activation. Finally, the molecular docking study demonstrated that ISL bound to Syk directly with the K (© 2024 The Scandinavian Foundation for Immunology.) |
| References: | Zhang Z, Yung KK, Ko JK. Therapeutic intervention in cancer by Isoliquiritigenin from licorice: a natural antioxidant and redox regulator. Antioxidants (Basel). 2022;11(7):1349. Wang L, Wang X, Kong L, et al. Isoliquiritigenin alleviates LPS/ D‐GalN‐induced acute liver failure by activating the PGC‐1alpha/Nrf2 pathway to reduce oxidative stress and inflammatory response. Int Immunopharmacol. 2021;100:108159. Sun J, Zhang Q, Yang G, et al. The licorice flavonoid isoliquiritigenin attenuates mycobacterium tuberculosis‐induced inflammation through Notch1/NF‐kappaB and MAPK signaling pathways. J Ethnopharmacol. 2022;294:115368. Liao Y, Tan RZ, Li JC, et al. Isoliquiritigenin attenuates UUO‐induced renal inflammation and fibrosis by inhibiting Mincle/Syk/NF‐kappa B signaling pathway. Drug Des Devel Ther. 2020;14:1455‐1468. Zhao H, Zhang X, Chen X, et al. Isoliquiritigenin, a flavonoid from licorice, blocks M2 macrophage polarization in colitis‐associated tumorigenesis through downregulating PGE2 and IL‐6. Toxicol Appl Pharmacol. 2014;279(3):311‐321. Li W, Sun YN, Yan XT, et al. Flavonoids from Astragalus membranaceus and their inhibitory effects on LPS‐stimulated pro‐inflammatory cytokine production in bone marrow‐derived dendritic cells. Arch Pharm Res. 2014;37(2):186‐192. Pouwels S, Sakran N, Graham Y, et al. Non‐alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63. Barreby E, Chen P, Aouadi M. Macrophage functional diversity in NAFLD ‐ more than inflammation. Nat Rev Endocrinol. 2022;18(8):461‐472. Kazankov K, Jorgensen SMD, Thomsen KL, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2019;16(3):145‐159. Karlmark KR, Weiskirchen R, Zimmermann HW, et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology. 2009;50(1):261‐274. Seki E, de Minicis S, Inokuchi S, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology. 2009;50(1):185‐197. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537‐2564. Yi YS, Son YJ, Ryou C, Sung GH, Kim JH, Cho JY. Functional roles of Syk in macrophage‐mediated inflammatory responses. Mediat Inflamm. 2014;2014:270302. Zewinger S, Reiser J, Jankowski V, et al. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat Immunol. 2020;21(1):30‐41. Zhang L, Yang SY, Qi‐Li FR, et al. Administration of isoliquiritigenin prevents nonalcoholic fatty liver disease through a novel IQGAP2‐CREB‐SIRT1 axis. Phytother Res. 2021;35(7):3898‐3915. Wang H, Fu Y, Da BB, Xiong G. Single‐cell sequencing identifies the heterogeneity of CD8+ T cells and novel biomarker genes in hepatocellular carcinoma. J Healthc Eng. 2022;2022:8256314. Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;362(12):1082‐1089. Rigsby RE, Parker AB. Using the PyMOL application to reinforce visual understanding of protein structure. Biochem Mol Biol Educ. 2016;44(5):433‐437. Chen F, Liu H, Sun H, et al. Assessing the performance of the MM/PBSA and MM/GBSA methods. 6. Capability to predict protein‐protein binding free energies and re‐rank binding poses generated by protein‐protein docking. Phys Chem Chem Phys. 2016;18(32):22129‐22139. Schwabe RF, Tabas I, Pajvani UB. Mechanisms of fibrosis development in nonalcoholic Steatohepatitis. Gastroenterology. 2020;158(7):1913‐1928. Luo X, Li H, Ma L, et al. Expression of STING is increased in liver tissues from patients with NAFLD and promotes macrophage‐mediated hepatic inflammation and fibrosis in mice. Gastroenterology. 2018;155(6):1971‐1984.e4. Biasizzo M, Kopitar‐Jerala N. Interplay between NLRP3 Inflammasome and autophagy. Front Immunol. 2020;11:591803. Hu X, Ding S, Lu G, et al. Apolipoprotein C‐III itself stimulates the Syk/cPLA2‐induced inflammasome activation of macrophage to boost anti‐tumor activity of CD8(+) T cell. Cancer Immunol Immunother. 2023;72:4123‐4144. Ahinko M, Niinivehmas S, Jokinen E, Pentikainen OT. Suitability of MMGBSA for the selection of correct ligand binding modes from docking results. Chem Biol Drug Des. 2019;93(4):522‐538. Barker MD, Liddle J, Atkinson FL, et al. Discovery of potent and selective spleen tyrosine kinase inhibitors for the topical treatment of inflammatory skin disease. Bioorg Med Chem Lett. 2018;28(21):3458‐3462. Lee YK, Chin YW, Bae JK, Seo JS, Choi YH. Pharmacokinetics of isoliquiritigenin and its metabolites in rats: low bioavailability is primarily due to the hepatic and intestinal metabolism. Planta Med. 2013;79(17):1656‐1665. Zhang K, Wang Q, Yang Q, et al. Enhancement of Oral bioavailability and anti‐hyperuricemic activity of Isoliquiritigenin via self‐microemulsifying drug delivery system. AAPS PharmSciTech. 2019;20(5):218. Wang N, Wang Z, Peng C, et al. Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via beta‐catenin/ABCG2 signaling. Carcinogenesis. 2014;35(11):2544‐2554. Wang N, Wang Z, Wang Y, et al. Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF1 demethylation. Oncotarget. 2015;6(12):9854‐9876. |
| معلومات مُعتمدة: | 82272809 National Natural Science Foundation of China; 82241043 National Natural Science Foundation of China; 81873866 National Natural Science Foundation of China; 81873867 National Natural Science Foundation of China; BE2022775 Social Development Foundation of Jiangsu Province, China; YZ2023248 Cultivation Foundation of Yangzhou Municipal Key Laboratory |
| فهرسة مساهمة: | Keywords: NAFLD; Syk; inflammasome; isoliquiritigenin; macrophage |
| المشرفين على المادة: | B9CTI9GB8F (isoliquiritigenin) EC 2.7.10.2 (Syk Kinase) 0 (Chalcones) 0 (Inflammasomes) EC 2.7.10.2 (Syk protein, mouse) |
| تواريخ الأحداث: | Date Created: 20240427 Date Completed: 20240610 Latest Revision: 20240610 |
| رمز التحديث: | 20240610 |
| DOI: | 10.1111/sji.13371 |
| PMID: | 38671579 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1365-3083 |
|---|---|
| DOI: | 10.1111/sji.13371 |